A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder
about
Vortioxetine for depression in adultsVortioxetineProfile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literatureThe safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.Chronic Vortioxetine Treatment Reduces Exaggerated Expression of Conditioned Fear Memory and Restores Active Coping Behavior in Chronically Stressed RatsPharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder.A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agUnder the Influence: The Interplay among Industry, Publishing, and Drug Regulation.A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus.Vortioxetine: a New Treatment for Major Depressive Disorder.Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension studyMultimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats.A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis.The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis.Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trialsDepression and cerebrovascular disease: could vortioxetine represent a valid treatment option?Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorderA randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trialsMulti-modality: a new approach for the treatment of major depressive disorder.New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder.Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorderThe effect of vortioxetine on overall patient functioning in patients with major depressive disorder.Serotonin and beyond: therapeutics for major depression.Neural plasticity and proliferation in the generation of antidepressant effects: hippocampal implication.Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunctionVortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Vortioxetine for the treatment of depression.Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.Vortioxetine: a review of its use in major depressive disorder.A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.The efficacy of vortioxetine for the treatment of major depressive disorder.Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary.A randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.
P2860
Q24186313-F8B8663E-07FD-455A-ACFD-22D05B6F05D9Q26773284-D0143B59-F3DD-40BC-9BAC-5B6FF4BBEC64Q26796436-6B042732-A477-42C4-A98E-EB0F6829A7A0Q31044175-FAF601ED-0753-4682-8EE2-5ABB9F0094E4Q33614804-4C8F0141-3523-4967-BA89-EA5D11A2824FQ33933912-5C399864-1D49-48AF-82BC-170E641107F6Q34041642-6AA515C8-5957-40C8-976A-FDDE970CCCCAQ34046215-07364C85-970A-47A5-8B2E-297D51E4568EQ34172150-05ABE70B-8F08-4D23-88EA-89065C17E078Q34497909-D6AB3692-408A-481D-9516-22A6F7AA78F0Q34505291-606FE33B-DA58-4299-95F6-A0C4708236FCQ34505568-1363AEDB-D135-4A62-950D-F33B9A22697FQ34531545-D42667AB-354B-4C59-A58A-67E93F269F19Q34559591-CE7D42DD-2EC7-48AB-8AE0-6678093EBA7FQ34637400-CFCBC897-04CA-494B-9DBB-A54248EC657DQ34676776-2D6836F0-BCF4-4B56-8FDC-8126A62A8345Q35066804-AE70C1BC-5E9E-401A-9EF8-AC4CF4D2302BQ35154113-AD11F6BD-D234-4F21-9089-8679C8117FCBQ35162633-35F1AD9D-03ED-4FBD-B48C-A735F7E16B5EQ35280477-D4328E82-2511-47C3-9ED3-0268E71C5B90Q35426685-B4491B64-DC16-4568-8D64-334AED4A90A6Q35536869-35A583D2-D48B-489E-8F31-4CB95172057FQ35607556-F596211C-9D77-4948-948F-ADDB4D999A5BQ36653073-371FC8DA-D5A1-41F5-B22F-C9A14939408DQ36896252-63194C84-F84A-41BB-AB31-1285BA5538CAQ37601281-71379CBB-D7B4-439F-B956-AD3D57F28964Q37692558-257DFA4C-F98A-4580-BDD0-08B71129E1DCQ37694366-0A5B4200-7EA7-489D-8F5B-206C9BCA4597Q38084600-53EC9676-3BC9-41AD-A710-1558791D967EQ38122158-9E6E686D-8C93-4A03-BBCE-01A3C465F39CQ38125568-3C16A2CA-DC7E-486C-875B-CA89ECF725F2Q38156001-929278A1-77C5-489F-A219-D1B75D8CBFF8Q38199987-DEB3EBD4-D3EE-4444-9B7C-7563707C299FQ38200656-5037F6D6-6ACB-4CFA-ACEF-9A6D7D7A9EA0Q38242001-C7B5C2B0-9B22-4020-9417-06C5F9369CB9Q38249999-4DE39109-6459-4062-BAC8-754D4D4F131EQ38270790-E8F8ABFB-E51C-4DB4-86FE-A29DDE2DCE48Q38271646-90F19F0E-3C41-4EBA-9F4F-2DE9F4115FC2Q38371388-EC1EC3FD-1EB0-40F8-A88A-9E4FADE28C0DQ38506798-700F4C08-FF8F-41B6-ABFC-2798817736C7
P2860
A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A double-blind, randomized, pl ...... with major depressive disorder
@ast
A double-blind, randomized, pl ...... with major depressive disorder
@en
A double-blind, randomized, pl ...... with major depressive disorder
@nl
type
label
A double-blind, randomized, pl ...... with major depressive disorder
@ast
A double-blind, randomized, pl ...... with major depressive disorder
@en
A double-blind, randomized, pl ...... with major depressive disorder
@nl
prefLabel
A double-blind, randomized, pl ...... with major depressive disorder
@ast
A double-blind, randomized, pl ...... with major depressive disorder
@en
A double-blind, randomized, pl ...... with major depressive disorder
@nl
P2093
P2860
P921
P1476
A double-blind, randomized, pl ...... with major depressive disorder
@en
P2093
Enric Alvarez
Francesc Artigas
Henrik Loft
Marianne Dragheim
P2860
P304
P356
10.1017/S1461145711001027
P407
P50
P577
2012-06-01T00:00:00Z